Target intelligence / Profile preview

Hydroxyapatite and amorphous calcium phosphate (Hydroxyapatite (HA); Amorphous calcium phosphate (ACP))

Target: Hydroxyapatite (HA); Amorphous calcium phosphate (ACP)
Molecular classification: Other: Inorganic biomineral, Ceramic biomaterial

Overview

Hydroxyapatite is the naturally occurring crystalline form of calcium phosphate that constitutes the primary mineral component of bone and dental enamel. Its chemical formula is Ca₁₀(PO₄)₆(OH)₂. Amorphous calcium phosphate (ACP) is a non-crystalline precursor phase to hydroxyapatite, involved in biomineralization, structural assembly of bone and tooth enamel, and osteogenic processes. ACP can transform into hydroxyapatite with the help of biological additives, facilitating the formation of highly ordered mineralized tissues.

Other names: Hydroxyapatite: HAhydroxyapatite mineralbone mineralAmorphous calcium phosphate: ACPnon-crystalline calcium phosphate

Mechanism of action

Remineralization: delivery of calcium/phosphate ions or fluorides to enhance hydroxyapatite formation; Scaffold: osteoconductivity and osteoinductivity to promote bone cell attachment, differentiation, and growth; Additive-mediated assembly: biological molecules (e.g., glycine, glutamic acid, amelogenin) guide ACP transformation to hydroxyapatite

Biological functions

Skeletal mineralizationTooth enamel formationBone repair and regenerationScaffold for osteogenic cellsRemineralization of dental tissue

Disease associations

Bone defects/fractures (as regenerative biomaterials)Calcific tendinitis (hydroxyapatite deposition pathology)Dental caries prevention (remediation via remineralization)Kidney stones (calcium phosphate stones)

Safety considerations

Mechanical weakness compared to natural bone (risk of fracture if used as implant material)Pathological calcification (hydroxyapatite deposits leading to tendinitis or kidney stones)Biodegradation rate and integration with host tissue (challenge for biomaterial design)

Interacting drugs

Fluoride ions (encourage transition from hydroxyapatite to fluorapatite for enamel strengthening)

2 more in the full profile.

Biomarkers

Calcium and phosphate levels (general indicators for bone health and formation)Hydroxyapatite presence in tissue (can be detected to confirm mineralization)No validated use as patient selection biomarkers for therapeutics—more relevant in material engineering or diagnostic contexts.

Beyond the preview

Go deeper on Hydroxyapatite and amorphous calcium phosphate (Hydroxyapatite (HA); Amorphous calcium phosphate (ACP)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hydroxyapatite and amorphous calcium phosphate (Hydroxyapatite (HA); Amorphous calcium phosphate (ACP)).

Explore the full profile